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Abstract
Lactate accumulation in tumors has been associated with metastases and poor overall survival in cancer patients. Lactate
promotes angiogenesis and metastasis, providing rationale for understanding how it is processed by cells. The
concentration of lactate in tumors is a balance between the amount produced, amount carried away by vasculature and if/
how it is catabolized by aerobic tumor or stromal cells. We examined lactate metabolism in human normal and breast tumor
cell lines and rat breast cancer: 1. at relevant concentrations, 2. under aerobic vs. hypoxic conditions, 3. under conditions of
normo vs. hypoglucosis. We also compared the avidity of tumors for lactate vs. glucose and identified key lactate catabolites
to reveal how breast cancer cells process it. Lactate was non-toxic at clinically relevant concentrations. It was taken up and
catabolized to alanine and glutamate by all cell lines. Kinetic uptake rates of lactate in vivo surpassed that of glucose in
R3230Ac mammary carcinomas. The uptake appeared specific to aerobic tumor regions, consistent with the proposed
‘‘metabolic symbiont’’ model; here lactate produced by hypoxic cells is used by aerobic cells. We investigated whether
treatment with alpha-cyano-4-hydroxycinnamate (CHC), a MCT1 inhibitor, would kill cells in the presence of high lactate.
Both 0.1 mM and 5 mM CHC prevented lactate uptake in R3230Ac cells at lactate concentrations at #20 mM but not at
40 mM. 0.1 mM CHC was well-tolerated by R3230Ac and MCF7 cells, but 5 mM CHC killed both cell lines 6 lactate,
indicating off-target effects. This study showed that breast cancer cells tolerate and use lactate at clinically relevant
concentrations in vitro (6 glucose) and in vivo. We provided additional support for the metabolic symbiont model and
discovered that breast cells prevailingly take up and catabolize lactate, providing rationale for future studies on
manipulation of lactate catabolism pathways for therapy.
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Introduction
Normal physiologic range of lactate concentration in the blood
is , 0.5–2 mM [1]; in contrast, pathophysiologic lactate
concentrations in tumors range from normal lactate levels to
concentrations as high as 40 mM [2]. In the 1920s Otto Warburg
was the first to discover that tumors accumulate excess lactate [3–
5]. In the last hundred years, the importance of this metabolic
switch in tumor tissue has become increasingly evident, and,
recently, elevated lactate levels in tumors has been coined as a
hallmark of cancer by Hanahan and Weinberg [6].
Lactate accumulation within tumor tissue is mainly due to the
increased glycolytic rate of cancer cells. This increase in glycolysis
is in response to a number of factors: hypoxia (Pasteur Effect),
proliferative demand, increased oxidative stress and altered genetic
programming [7–9]. Increases in lactic acid in tumors combined
with lack of buffering capacity contribute to localized areas of low
pH in tumors [7,8]. It has been observed that lactate accumulation
is correlated with hypoxia in some tumor types [10] (Pasteur
Effect), and, clinically, hypoxia is correlated with poor patient
prognosis and survival [11,12]. However, high lactate is not a
surrogate marker of hypoxia. Studies of genomic regulation by
hypoxia vs. lactate vs. acidosis in cancer cells showed that lactate
regulated a different set of genes than hypoxia [13]. The
consequences of downstream lactate signaling in normal mam-
mary epithelial cells exposed to high lactate showed repression of
glycolytic genes. In several large breast cancer clinical series where
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gene expression data were available, the ‘‘lactic acidosis’’ genomic
signature with repressed glycolysis was associated with significantly
increased patient survival rates [13]. This indicates that the
response of the tumor to high lactate is important to patient
outcome and that lactate utilization and catabolism by the tumor
warrants investigation in order to understand how cancer cells
cope with high lactate concentrations.
Monocarboxylate transporters (MCTs) facilitate movement of
lactate in and out of the cell. There are 14 different subtypes, four of
which are relatively well-characterized: MCT1, MCT2, MCT3 and
MCT4 [14,15]. Of these, MCT1 is the most ubiquitously expressed
subtype. MCT1 inhibition has been receiving attention as a
potential anti-cancer treatment option [16,17]. We previously
reported that lactate can serve as an energy source for aerobic cells
and proposed a ‘‘metabolic symbiont’’ model within the tumor
microenvironment. In this model, lactate produced by hypoxic cells
can provide an additional substrate for aerobic cells. With the
aerobic cells utilizing the lactate for energy, they will utilize less
glucose, thereby allowing some glucose to reach the hypoxic cells
[17]. We found that SiHa (cervical cancer) cells, which expressed
higher levels of MCT1 but lower levels of MCT4, consumed
significantly more lactate and less glucose than WiDr (colorectal
cancer) cells. Conversely, WiDr cells, which expressed higher levels
of MCT4 and lower levels of MCT1, consumed less lactate and
more glucose than SiHa cells [17]. Recently, MCT subtype and
LDH isoform expression has been characterized in HMEC, MCF7
and MDA-MB-231 cells [18]. HMEC display the greatest amount
of MCT1 expression on the cell membrane and express both LDHA
and LDHB. MCF7 cells display MCT1 expression on the cell
membrane in lower levels than HMEC and express both LDHA
and LDHB. MCF7 cells exhibit higher LDHB expression than
MDA-MB-231 cells. MDA-MB-231 cells do not express MCT1.
They express both LDHA and LDHB, with higher LDHA than
MCF7 cells. This suggests that there is a connection between MCT
subtype expression and a lactate-consuming ability in cancer cells.
Given these differences of expression of MCT subtypes [18] and our
previous findings of lactate consumption in connection with MCT
subtype expression [17], we hypothesized that lactate uptake and
catabolism would be different between the breast cells.
Lactate transport can be manipulated by MCT-inhibitors [17].
The small molecule MCT-inhibitor a-cyano-4-hydroxycinnamate
(CHC) is .10 fold more selective for inhibition of MCT1 than for
inhibition of MCT4 [19]. It was proposed that inhibition of
MCT1 by CHC or knockdown of MCT1 using siRNA would
prevent lactate uptake in the aerobic cells, forcing them to utilize
glucose, thereby starving the more treatment-resistant hypoxic
cells [17]. In cell-based assays it was shown that CHC decreases
lactate-fueled respiration and ATP production in both SiHa and
WiDr cells [17]. It was also shown that treatment with CHC
significantly decreased tumor growth similar to siMCT1 in
xenograft models [17]. These results warrant further investigation
of MCT1 inhibition as an anti-tumor treatment option. It has
already been reported that MCT1 inhibition can lead to cancer
cell death via a lethal decline in pHi with blockade of endogenous
lactic acid exportation [20]. We hypothesized that pharmacolog-
ical inhibition of exogenous lactate metabolism with CHC could
elicit cell death by preventing exogenous lactate entry and
utilization in glucose-deprived conditions.
Our cell-based studies focused on four cell lines: Human
mammary epithelial cells (HMEC), MCF7 (human mammary
adenocarcinoma), MDA-MB-231 (human mammary adenocarci-
noma), and R3230Ac (rat mammary carcinoma) cells. HMEC
cells were included to compare a normal cell response to
exogenous lactate with cancer cell responses to lactate. Catabolism
studies were also conducted on HUVEC cells as a second normal
tissue line. The R3230Ac rat mammary carcinoma was used as
our in vivo model, because we have studied glucose uptake and its
conversion to lactate previously in this model previously [21,22].
Both MCF7 and MDA-MB-231 cells were included as breast
cancer models for two primary reasons. First, we wanted to
represent a luminal (MCF7) and a basal-like (MDA-MB-231)
breast cancer subtype [23], as these subtypes are known to be
considerably different clinically and pathologically [23-25]. Sec-
ond, it has previously been reported that MCT1 is silenced in
MDA-MB-231 cells [18,26]. By including both MDA-MB-231
and MCF7 cells in our experiments, we could compare lactate
uptake and metabolism in breast cancer cells lacking and
expressing MCT1. Though our studies did not focus on p53
signaling and lactate metabolism, it is important to mention that
the p53 status in each of these cell lines differ considerably:
R3230Ac and MCF7 cells are p53 WT [27–29] while MDA-MB-
231 cells are p53 null [30,31]. This may be an important avenue
for future investigation because p53 influences many metabolic
pathways including glycolysis, oxidative phosphorylation and
mTOR signaling [32,33].
In this study, we expanded on our prior work on lactate
metabolism, focusing on breast cancer. The main goals were: 1) to
establish the tolerance of breast cancer cells to a range of lactate
concentrations typical of that seen in human breast cancer, 2) to
investigate lactate catabolism in vitro and in vivo and 3) to examine
whether treatment with CHC elicits cell death in a lactate-
dependent manner. We used two doses of CHC sufficient to
inhibit MCT1; one concentration chosen (5 mM) was based on
previous studies, and the other concentration chosen was based on
reported Ki values for the compound [14,17]. To investigate
lactate metabolism in vivo, we employed the R3230Ac tumor
model, which has been shown to exhibit regions of high lactate in
the absence of measureable glucose [10].
Results
Lactate accumulation occurs in locally advanced breast
cancer (LABC) with a median concentration range of 0.6 –
8.0 mmol/g, and lactate accumulation shows high intra-
tumoral variation
Lactate concentrations have been measured in human head and
neck [34], cervical [2] and colorectal [35] cancers by biolumines-
cent technology. Lactate levels in breast cancer have not
previously been measured. We sought to define the range of
lactate concentrations found in LABC, to guide our cell-based
assays. Twenty-three frozen breast-core biopsies from 21 patients
with locally advanced breast cancer (LABC) (two biopsies were
from the same patient, different sites of the tumor) were made
available to us from an Institutional Review Board (IRB)-approved
phase I/II clinical trial conducted at Duke University (Table 1).
Lactate concentrations were measured with bioluminescence
imaging [10,36,37] (Fig 1A). The median lactate concentration for
the entire sample set was 4.4 mmol/g. Samples could be divided
into low v. high lactate groups based on this median (Table 1). The
range of median lactate values for LABC biopsies was 0.6 to
8.0 mmol/g, and the median range for benign breast tissue (‘‘bb’’)
was 0.8 – 1.9 mmol/g (Fig 1B). The quartile range and 95%
confidence intervals demonstrated a wide range of lactate values;
the 95th percentile showed lactate levels greater than12 mmol/g
(Fig 1B). These results illustrate the heterogeneity in lactate
accumulation within individual tumors and between tumors.
However, these concentrations were considerably lower than seen
in other tumor types. For example, in head and neck cancer,
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median values were in the range of 7 mmol/g with microregional
variation extending as high as 40 mmol/g [2,34]. Two of three
biopsies that did not have any invasive cancer (‘‘bb’’) showed lower
lactate accumulation than the majority of biopsies with invasive
cancer (Fig 1B).
The two specimens that represented second biopsy site from the
same patient (stars, Fig 1B) fell into the same high or low lactate
group as the first biopsy site (Table 1). Specimens LABC1 and
LABC10 are biopsies from the same patient and are in the low
lactate group, while specimens LABC15 and LABC21 (Fig 1B) are
from another patient and are in the high lactate group (second site
indicated by ‘‘d’’ in Table 1). The median lactate concentrations
measured in LABC1 and LABC10 (0.6 and 4.3 mmol/g) were
significantly different (Student’s T-test, p , 0.05), while the
median lactate concentrations measured in LABC15 and LABC21
(5.1 and 8.0 mmol/g, respectively) were not (Fig 1B, Table 1).
From these dual biopsy sites from one tumor, the intra-tumor
metabolic heterogeneity is illustrated, indicating that lactate levels
can vary significantly among different areas of the same tumor.
Lactate uptake and metabolism occurs in vitro in
R3230Ac cells
Before studying lactate metabolism in cells it was important to
assess cell viability after lactate treatment to ensure that the
metabolic results would not be skewed by dying cells. The range of
lactate concentrations tested in vitro was defined by our experi-
mental findings in LABC (Fig 1) and the literature on lactate
accumulation in tumors [2,22,34,35,38–40]. Concentrations of 5
and 10 mM lactate reflect the concentrations found in the LABC
biopsies and the median lactate concentration found in other solid
tumors, such as head and neck and cervical cancer [2,34,38]. It
was previously published that microregions of some tumors can
reach up to 40 mM lactate [2], which we defined as our upper
limit. 20 mM lactate was included in some experiments as an
intermediary concentration between the low and high limits;
however, this concentration was still higher than what was found
in the clinical LABC specimens. The acute effects of lactate
toxicity were examined using Annexin V and 7-aminoactinomycin
D (7-AAD) to assess apoptosis and membrane integrity, respec-
tively, in cells exposed to lactate (0, 10, 20 and 40 mM) for 24 h
(Fig S1 and S2). These studies were conducted in the presence (Fig
S1) and absence of glucose (Fig S2) because it has been reported
that lactate accumulation can occur in the presence or absence of
glucose in vivo [10]. Additionally, we chose to use glucose-free
media for a majority of our NMR studies in order to acquire
higher signals for lactate and lactate-generated metabolites. When
exogenous sodium lactate was supplemented in cell culture media
containing glucose, none of the cells showed any decrease in cell












Lo [L] bb1 0 alive 2 n n 39 0.0 0.0 0.8 1.5 2.6
LABC1 70 alive 2 n n 62 0.0 0.0 0.6 1.3 2.5
bb3 0 alive 3 n n 54 0.6 1.7 2.5 3.9 4.8
LABC2 30 alive 3 n n 62 0.3 1.5 2.6 3.5 5.2
LABC3 70 alive 3 n n 55 0.6 1.8 2.9 3.8 5.4
LABC4 95 alive 4 y n 32 0.4 1.8 3.3 3.7 5.4
LABC6 80 dead 4 y n 63 1.1 2.5 3.8 4.9 7.0
LABC7 75 dead 4 y y 58 1.2 2.7 4.0 5.2 7.2
LABC8 75 alive 3 n n 55 1.4 2.9 4.2 5.3 7.5
LABC9 70 alive 3 n n 43 1.4 3.0 4.2 5.5 7.7
LABC710(d) 65 alive (d) 2 (d) n (d) n (d) 62 (d) 1.7 3.1 4.3 5.3 7.1
bb4 0 alive 2 n n 35 0.7 2.5 4.4 5.5 7.8
Hi [L] LABC11 70 dead 4 y y 75 1.6 3.1 4.5 5.7 7.8
LABC12 75 dead 4 y ? 66 0.9 2.6 4.5 5.1 7.2
LABC13 80 alive 2 n n 44 1.5 3.2 4.6 5.7 7.8
LABC14 60 alive ? ? ? ? 1.5 3.3 5.0 6.3 8.9
LABC15 95 alive 3 n n 35 1.0 2.9 5.1 5.7 8.6
LABC16 80 dead 3 n y 32 1.6 3.1 5.2 6.0 8.2
LABC17 80 alive 3 n y 49 2.0 3.7 5.2 6.6 8.9
LABC18 80 dead 2 n n 27 1.8 3.8 5.6 7.0 9.4
LABC19 75 alive 4 y n 52 2.9 4.9 6.6 8.1 10.9
LABC20 80 alive 3 n n 43 3.3 5.3 7.2 8.8 12.3
LABC21(d) 90 alive (d) 3 (d) n (d) n (d) 35 (d) 4.0 6.0 8.0 9.4 12.2
Specimens are named based on presence of benign breast tissue (bb) or presence of invasive cancer (LABC). Duplicate specimens are indicated (d). Measured lactate
concentrations (mmol/g of tissue) are displayed in the last five columns. These values correspond to the lactate concentration range ([L]) seen in microregions in each
specimen: fifth percentile/minimum (5P), twenty-fifth percentile (25P), fiftieth percentile/median (50P), seventy-fifth percentile (75P) and ninety-fifth percentile/
maximum (95P). Samples are arranged in ascending order of median lactate concentrations. High and low lactate groups were determined based on median lactate
concentrations .4.4 mmol/g. LABC5 and bb2 specimens are missing due to unavailable clinical information on these patients.
doi:10.1371/journal.pone.0075154.t001
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viability or increase in cell death responses (Fig S1). Likewise, all
cell lines treated with 0 –20 mM in glucose-deprived conditions
survived (Fig S2). Only at 40 mM lactate (- glucose) did MCF7
and MDA-MB-231 cells show significant cell death responses
(FigS2F&G). Glucose deprivation usually elicits cell stress respons-
es, such as activation of JNK1 and increased oxidative stress [41–
45]. This may suggest that very high lactate concentrations can
augment the cellular stress elicited by glucose deprivation, but
40 mM lactate has been reported very infrequently in solid tumors
and concentrations this high were not found in any of the breast
tumor biopsies evaluated in this study [2,10,34,38,39,46,47].
Thus, we conclude that cell viability is not appreciably affected
over the range of physiologically relevant lactate concentrations
observed in breast cancer (Fig 1) with or without glucose.
We hypothesized that normal breast cells and breast cancer cells
could utilize exogenous lactate for metabolic purposes. We used
NMR with 13C-labeled lactate to track uptake; we first focused on
the lactate metabolism in R3230Ac cells. In vitro, R3230Ac cells
took up lactate in a concentration-dependent manner after 4 h of
treatment (Fig 2A; lactate peaks indicated by arrows). In glucose-
deprived conditions, R3230Ac cells were treated with 5 mM
3-13C-lactate for 12 h. The 13C spectra of the cell lysate show
peaks corresponding to 13C-lactate, 13C-alanine and 13C-gluta-
mate (Fig 2B). When these metabolites were normalized to protein
levels, glutamate was the most abundant (Figure 2C). To
determine if lactate would be metabolized in the presence of
glucose, 5 mM concentrations of U-13C-lactate and 1-13C-
glucuose were infused in tumor-bearing rats. The utilization of
universally labeled lactate allows one to distinguish the uptake and
metabolism of lactate from the blood as opposed to lactate and
other metabolites produced from glucose. In Figure 2D, the first
three peaks are for lactate, and the next three peaks are for
alanine. Due to the different position of 13C, the lactate
metabolized from 1-13C-glucose is separated from universally
labeled lactate; a similar pattern emerges with alanine metabolized
from lactate or glucose. The ratio of universally labeled lactate
taken up by the tumor versus lactate produced from glucose was
0.36. Additionally, alanine is produced from both glucose and
lactate. The results indicate that the tumor takes up lactate even in
the presence of glucose. This is the first time a breast tumor has
been shown to simultaneously take up lactate and glucose and
metabolize both substrates in vivo.
Lactate transport is dependent upon expression of proton-
coupled, lactate-specific transporters of the monocarboxylate
transporter (MCT) family. MCTs are passive, bidirectional
transporters with different Km constants for lactate(MCT1 =
,3–5 mM, MCT2 = ,0.7 mM and MCT4 = ,28 mM) [14].
MCT1 has ubiquitous tissue distribution but is found to be
upregulated in cancer [48–51]. MCT4 has a more specific tissue
distribution; it is associated primarily with glycolytic cells/tissues
Figure 1. Human tumor samples measured for lactate with bioluminescence ex vivo show lactate concentrations vary considerably
between samples. Bioluminescence color map for lactate concentrations measured in a LABC patient biopsy (A). Tumor regions are outlined and
marked (T). Waterfall Box & Whisker plot for lactate concentrations (mmol/g) measured in benign breast tissue (bb) and LABC patient biopsies (B).
Stars indicate separate biopsies from the same patient. LABC1 and LABC10 samples show a significant difference in lactate concentrations ({p,0.05,
Student’s T-test). First quartile values represented in red; third quartile values are represented in green. Median values represented at the interface of
red and green boxes. Error bars represent the 5th and 95th percentile lactate concentrations. All biopsies n = 3–4.
doi:10.1371/journal.pone.0075154.g001
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and is regulated by the hypoxia inducible transcription factor,
HIF-1 [52–54]. Previously, we have shown that cancer cell lines
with high MCT1/low MCT4 expression consume more lactate
than cancer cell lines with low MCT1/high MCT4 expression
[17].
Although it is well-documented that most normal cells and
cancer cells typically express MCT1 [14,48–51], MCT1 expres-
sion in R3230Ac cells has not been tested previously. R3230Ac
tumor shows abundant membrane expression of MCT1 (Fig 2E),
while MCT4 was undetectable (Fig S3B), consistent with a lactate-
consuming phenotype. It has previously been reported that
R3230Ac cells utilize oxidative phosphorylation as well as
glycolysis [55]. Glutamate was found to be the predominant
lactate-derived metabolite produced in R3230Ac cells in vitro (Fig
2B). Glutamate is a TCA cycle by-product, formed from a-
ketoglutarate. This indicates that one pathway of lactate metab-
olism is respiration. In addition to glutamate formation indicating
cellular respiration of lactate, R3230Ac cells were treated with
increasing concentrations of lactate (-glucose) in vitro, and oxygen
consumption rate was measured. All concentrations of lactate $
10 mM tested showed a significant increase in oxygen consump-
tion rate in the cells (Fig 2F), providing further evidence that
lactate is consumed via respiration.
Kinetic uptake of glucose and lactate in vivo show lactate
uptake in R3230Ac tumors occurs more rapidly than
glucose uptake
Kinetics of glucose and lactate uptake, retention, and clearance
were measured using a novel scintillation probe following i.v.
administration of either 14C-glucose (n = 9) or 14C-lactate (n = 3).
Figure 2. R3230Ac cells take up and metabolize lactate to alanine and glutamate in vitro and in vivo. 1H NMR of R3230Ac cell lysates
exposed to various concentrations of lactate for 4 h (glucose absent) showed a concentration-dependent lactate uptake (arrows, ,1.3 and ,1.6 ppm,
A). 13C NMR plot for R3230Ac cell lysate after 12 h treatment with 5 mM 3-13C-lactate (no glucose) showing generation of 13C-labeled glutamate and
alanine species (B). Dioxane was included as an internal standard which allowed quantification of labeled metabolites (C). 13C NMR plot from
R3230Ac tumor after infusion with equimolar concentrations of universally labeled U-13C-lactate and 1-13C-glucose showing uptake of U-13C-lactate
(,20.75 and ,21.25 ppm) and generation of U-13C-alanine species (,16.9 and 17.2 ppm) in the presence of labeled glucose and during production
of glycolytically-derived lactate (,21 ppm) and alanine (,17.1 ppm) (D). Tissue staining of R3230Ac tumor shows positive expression of MCT1
(green); areas of perfusion are indicated by Hoechst 33342 (blue) (E). Glucose-deprived R3230Ac cells show significantly increased oxygen
consumption (n = 3, Student’s T-test, p , 0.05) with increasing concentrations of exogenous lactate compared to the untreated control (F).
doi:10.1371/journal.pone.0075154.g002
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A three-compartment pharmacokinetic model was formed from
the data to determine rate constants for glucose and lactate uptake
by the tumor and subcutaneous (SQ) tissue (Fig S4). Rate constants
for 14C-glucose and 14C-lactate are summarized in Table 2, and
the time activity curves were shown in Figure 3A and 3B. Lactate
was cleared much faster from plasma than glucose. Furthermore,
the rate constant for the transfer of lactate from blood
compartment into the tumor was higher than that of glucose
(0.238 vs. 0.038), indicating much faster uptake of lactate than
glucose. The back flux rate (from tissue back to blood) was higher
in lactate compared to that of glucose (0.062 vs. 0.049). As the
scintillation probe only detects 14C signal, it was not possible to
determine if the back flux signal came from free glucose/lactate or
their metabolites. The uptake of both glucose and lactate was
higher in tumor compared to subcutaneous compartment indicat-
ing higher tumor metabolism. The PK analysis shows that
R3230Ac tumor tissue takes up lactate faster than glucose.
14C-lactate autoradiography was compared in hypoxic (indicated
by pimonidazole staining) v. perfused (indicated by Hoechst
staining) regions of R3230Ac tumor. We found that the labeled
lactate was taken up primarily in well-perfused tumor regions where
hypoxia was absent (Fig 3C&D). In one small tumor that did not
exhibit appreciable hypoxia, 14C-lactate was evenly distributed
throughout the whole section (Fig 3E&F). This data is consistent
with the proposed metabolic symbiont model [17], in which lactate
is preferentially taken-up by better oxygenated tumor regions.
To test if the same metabolites would be generated in vivo as in
vitro, 13C-lactate was infused into R3230Ac tumor-bearing rats.
Tumor, liver, brain and other organs were collected and snap-
frozen at time of sacrifice (15, 30, or 60 min). After 15 minutes,
labeled lactate was present in the tumor at 0.5 mM/g of tissue (Fig
3G). Glucose was not significantly produced from lactate. This
concentration was lower after 30 and 60 min, indicating metabolism
or clearance from the tumor tissue. Both glutamate and alanine
concentrations were increased in tumor after lactate infusion, with
alanine reaching the highest concentration at 30 minutes (Fig 3G).
This shows that the R3230Ac tumor utilizes lactate for metabolite
generation. Brain and liver tissue also showed an increase in lactate
uptake compared to baseline (Fig 3H&I), but the concentrations
seen were not as high as lactate uptake in the tumor. As expected,
liver produced glucose from the infused lactate (Cori Cycle).
Taken together, the kinetic results clearly showed: 1. lactate
uptake occurs in a rat mammary carcinoma model in vivo, 2. Tumor
tissue has a higher uptake of lactate than SQ tissue, 3. R3230Ac
tumors take up lactate more rapidly than glucose, 4. Lactate uptake
occurs in aerobic regions of the tumor, and 5. Glutamate and
alanine are generated from lactate in vivo. Previous studies have
shown that lactate uptake occurs in hepatoma [56], sarcoma [57],
and pancreatic cancer [58], and that lactate acts as preferred
substrate compared to glucose in gliomas [59,60]. Here, we have
shown for the first time that lactate is also preferentially taken up in
a breast cancer model with higher transfer rates than glucose.
Further studies with other tumor models would be required to verify
whether the preferential uptake of lactate is a class effect in breast
cancer. But at the very least, we show that lactate can be taken up
and metabolized in vivo, in the presence of glucose.
Human breast cells metabolize lactate to alanine and
glutamate
We questioned if human breast cells could also take up and
metabolize lactate. First, we screened the human breast lines
(HMEC, MCF7 and MDA-MB-231) for MCT1 and MCT4
expression (Fig S3). MCT1 was expressed in MCF7 and HMEC
cells but not MDA-MB-231 cells (Fig S3A), consistent with the
literature [18,26]. MDA-MB-231 was the only cell line that
expressed abundant MCT4 (Fig S3B). HMEC showed very little
MCT4 expression in the whole cell lysate, and MCT4 was
undetectable for MCF7 cells (Fig S3B). Hussien and Brooks
provide a more complete characterization of MCT subtype
expression in these same cell lines, as they investigated mitochon-
drial and membrane expression in addition to using whole cell
lysates.[18]. Briefly, their studies found MCT1 expression on the
plasma membrane of MCF7 and HMEC cells but not MDA-MB-
231 cells. MCT4 and MCT2 were found to be expressed in all
three cell lines, localizing to the plasma and mitochondrial
membranes [18]. Given these differences in MCT subtype
expression in cell lines, we hypothesized that lactate metabolism
among the breast lines would be different. Specifically, we
expected relatively little lactate uptake and metabolism in MDA-
MB-231 cells due to their lack of MCT1 expression.
Both malignant and nonmalignant human breast cell lines
showed evidence of intracellular 13C-lactate after 24 h treatment
(Fig 4A, arrows). This indicates that: 1. lactate uptake occurs in
both normal and cancer cells (Fig 4A). 2. lactate uptake is not
MCT1-dependent in MDA-MB-231 cells. MDA-MB-231 cells
have been documented to express MCT2 [18], which has a higher
affinity for lactate than MCT1 [14]. We then sought to compare
the rates of lactate uptake between human breast cancer cell lines.
We determined lactate concentrations in glucose-free cell media
from MCF7 or MDA-MB-231 cells incubated with supplemented
lactate (20 mM) over 5 days. The media was not replenished over
this time period. Because the lactate used was unlabeled, glucose-
free media was chosen so glycolytically-derived lactate would not
interfere with the measurement of lactate consumption. Figure 3B
illustrates the mean lactate concentration measurements for each
time point. Over 5 days, the decline in mean lactate concentra-
tions in the cell media was significantly greater for MCF7 cells
(18.3 mM drop) than for MDA-MB-231 cells (5.5 mM drop, p ,
0.0001, Fig 4B). When the individual time point measurements of
lactate concentration was applied to a linear regression analysis,
the rate coefficients of lactate consumption were significantly
different between MCF7 (4.01) and MDA-MB-231 (0.71) cells (p
, 0.0001). Cell counts at the beginning and end of lactate
treatment are displayed in Figure 4C; the increase in cell numbers
was not significantly different for MCF7 and MDA-MB-231 cells.
However, when cells were plated at equal densities and allowed to
grow in high-glucose complete media or treated with 20 mM
lactate (no glucose) for 5 days, MCF7 cell numbers showed no
difference between treatments. Conversely MDA-MB-231 cells
showed a significant increase in cell numbers when cultured in the
glucose-containing lactate-supplemented media (Fig S5). These
results show that MCF7 cells utilize lactate more effectively than




k1 Blood to tumor transfer rate 0.03860.008 0.23860.055 ,0.001
k2 Tumor to blood transfer rate 0.04960.006 0.06260.001 0.006
k3 Blood to SQ transfer rate 0.001660.0001 0.001460.0002 0.077
K4 SQ to blood transfer rate 0.06660.008 0.074460.009 0.166
Transfer rate constants were calculated from 14C-glucose (n = 9) and 14C-lactate
(n = 3) kinetic data using the compartmental model explained in the Methods
and Fig S3. Kinetic transfer rates of 14C-glucose were evaluated against the
transfer rates of 14C-lactate with a two-tailed Student’s T-test.
doi:10.1371/journal.pone.0075154.t002
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MDA-MB-231 cells and have less of a dependence on glucose for
cell growth than MDA-MB-231 cells. These results reinforce the
findings in our previous study [17] that cell lines with high
MCT1/low MCT4 consume more lactate than cell lines
expressing high MCT4/low MCT1.
HMQC plots generated from human breast cell lysates showed
evidence of 13C-labeled alanine, glutamate and pyruvate in human
normal breast cell lysates (Fig 4D) and human breast cancer cell lysates
(Fig 4E&F) after 24 h incubation with 10 mM 3-13C-lactate,
indicating that lactate can be catabolized in these cell lines and that
the metabolites generated are the same as those seen in R3203 Ac
cells. Taken together, these data show that MCF7 and MDA-MB-231
cells consume lactate at significantly different rates but produce similar
catabolites. Our original hypothesis that normal breast and breast
cancer cells would metabolize lactate differently was incorrect, as
HMEC cells showed the same metabolites generated from exogenous
lactate as breast cancer cell lines; however, the relative rates of lactate
utilization and catabolism for each cell line are different.
Lactate-derived metabolites are exported from cells
Since lactate was not toxic to cells in the physiologically relevant
range, we hypothesized that lactate-generated metabolites could
be released from cells after 24 h as a means to reduce levels within
the cells. Media and cell lysates from each breast cancer cell line
were collected after 24 h treatment with 5 mM 13C-lactate
(-glucose). Each of the cell lines showed 13C-labeled alanine and
glutamate in the media (Fig 4G). R3230Ac cells showed very little
lactate, alanine and glutamate in cell lysates after 24 h, indicating
that lactate metabolism is more rapid in these cells compared to
MCF7 or MDA-MB-231 cells, which both retained some 13C-
lactate in the lysate(Fig 4G). Additionally, there is evidence of a
greater amount of glutamate (peaks ‘‘1’’ and ‘‘2’’) in both the
Figure 3. Kinetic analyses of metabolites with radioactive probes show fast plasma clearance of lactate and lactate uptake in
perfused regions of R3230Ac tumors. Plots of individual metabolite and fitted pharmacokinetic standard uptake values (SUV) of 14C-labeled
glucose (100 mCi, A) and lactate (50 mCi, B) infused at a rate of 0.1 mL/min data for plasma, subcutaneous tissue (SQ) and R3230Ac tumor tissue over
160 minutes. R3230Ac tumors, grown in the flanks of Fischer 344 rats, show clearance of 14C labeled glucose (n = 6) from plasma from 6 SUV to 2 SUV
over 40 mins and maximum uptake of 14C labeled glucose in the tumor after 16 mins (A). 14C labeled lactate (n = 3) was cleared from the plasma (from
6 SUV to 2 SUV) in 14 mins and showed maximum uptake in the tumor after 14 mins (B). SUV = standard uptake rates. Autoradiography images (D-F)
of 14C-lactate uptake in R3230 Ac tumors show high lactate uptake (C&E) in well-perfused areas, as indicated by positive Hoechst 33342 staining
(blue, D&F), compared to hypoxic tumor regions, as indicated by positive pimonidazole staining (orange, D&F). R3230Ac tumors (G) show presence of
13C-lactate, 13C-alanine and 13C-glutamate at 15, 30 and 60 minutes after 13C-lactate infusion. All 13C metabolites are increased compared to baseline
levels (prior to infusion). 13C-lactate uptake and 13C-metabolite generation in brain (H) and liver (I) after 13C-lactate infusion show a slight increase in
metabolites compared to baseline but do not reach concentrations found in R3230Ac tumors.
doi:10.1371/journal.pone.0075154.g003
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R3230Ac and MCF7 cells compared to MDA-MB-231 cells (Fig
4G). Although lack of MCT1 expression in MDA-MB-231 cells
did not prevent lactate uptake, the lactate catabolism of these cells
was considerably less efficient than the R3230Ac or MCF7 cells.
Studies in normal cell lines (HMEC and HUVEC) also showed
lactate uptake and metabolite release into the media after
treatment with 10 mM lactate for 4.5 h (HMEC, Fig S6A&B) or
5 mM lactate for 24 h (HUVEC, Fig S6C). These results show that
excretion of lactate catabolites appears to be a universal trait,
shared between normal and tumor cells.
CHC prevents lactate uptake at lactate concentrations
#20 mM; CHC prevents lactate catabolism at lactate
concentrations of 40 mM
Alpha-cyano-4-hydroxycinnamate (CHC) is a small molecule
inhibitor of MCTs, with a ten-fold selectivity for MCT1 compared
to MCT4 [61]. Previously, we have shown that 5 mM CHC will
inhibit lactate uptake, decrease cellular ATP in SiHa and WiDr
cells and decrease tumorigenicity [17]; however, this study was not
conducted with breast cancer cell lines, and 5 mM CHC is a
rather high concentration [62]. It has been reported that
concentrations of CHC between 50-500 mM will inhibit MCT1,
and that the mitochondrial pyruvate carrier (MPC) is inhibited
with concentrations # 5 mM [14,63]. To span the range of
pharmacologically effective doses, we tested the effects of 5 and
0.1 mM CHC on cell viability and lactate metabolism. The
concentration of 5 mM CHC was included based on previous
studies [17,64]. The lower concentration (0.1 mM) was chosen
based on previous commentary [62] and evidence that 5 mM
CHC may elicit nonspecific cell death responses [65].
Using 13C-lactate (-glucose), we investigated the ability of 5 mM
CHC to prevent lactate uptake with low (5 mM) and high
Figure 4. Lactate uptake and metabolism in human breast cells and metabolite excretion. 13C NMR spectra of human breast lines
indicated evidence of 13C-lactate (arrow, 19 ppm) uptake after 24 h exposure to 10 mM 13C-3-lactate (A). Lactate measurements of cell media after 5
day incubation with 20 mM unlabeled sodium lactate in glucose-free media showed a significant difference in lactate consumption between MCF7
and MDA-MB-231 cells (mean overall decrease in lactate concentrations were 0.4 mM for the no-cell media control plate, 5.5 mM for MDA-MB-231
media and 18.3 mM for MCF7 media, n = 5, *p , 0.001 compared to MDA-MB-231 and media control, Student’s T-test, B). The increase in cell number
of MCF7 and MDA-MB-231 cells at the beginning (day 0) and end (day 5) of lactate treatment show no significant difference (C). Heteronuclear
multiple quantum coherence (HMQC) NMR plots of cell lysates treated for 24 h (n = 2) with 10 mM 3-13C-lactate (no glucose) showed 13C-lactate (dark
green ‘‘L’’) uptake and 13C-glutamate (blue ‘‘G’’), 13C-alanine (orange ‘‘A’’), and 13C-pyruvate (red ‘‘P’’) generation in HMEC (D), MCF7 (E), and MDA-
MB-231 cells (F). 13C NMR spectra of R3230Ac, MCF7 and MDA-MB-231 cell lysates (bottom) and media (top) show evidence of 13C-metabolites in the
media of each cell line and in the lysate of MCF7 and MDA-MB-231 cells after 24 h incubation with 40 mM lactate (G). Numeric labels: 1 = 13C-Glu c,
2 = 13C-Glu b, 3 = methyl 13C- lactate, 4 = methyl 13C-Ala
doi:10.1371/journal.pone.0075154.g004
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(40 mM) lactate concentrations (Fig 5A-C). Cell lysates from
R3230Ac cells show metabolism of 5 mM 13C-lactate to alanine
and glutamate after 4 h in the absence of CHC (Fig 5A, top).
When 5 mM CHC was added to the cell media with 5 mM 13C-
lactate (-glucose), the cell lysate did not show evidence of 13C-
lactate after 4 h (Fig 5A, bottom). When R3230Ac cells were
exposed to 40 mM 13C-lactate and 5 mM CHC for 4 h, cell
lysates showed a large 13C-lactate peak in the 13C spectrum (Fig
5B, top), and 13C-lactate was still present after 24 h (Fig 5B,
bottom). From previous observations, it is anticipated that all
lactate metabolites should be exported at this time point (Fig 4G).
The fact that a rather large 13C-lactate peak was still detected after
24 h indicates that treatment with 5 mM CHC may be more
effective at preventing lactate exportation than inhibiting uptake
when extracellular lactate concentrations were high. Because
CHC is a competitive inhibitor of MCT1, it is possible that lactate
enters the cell when extracellular concentrations are high due to
lactate outcompeting CHC. It should be noted that no 13C-
metabolites were present in the R3230Ac cell media treated with
40 mM 13C-lactate + 5 mM CHC, indicating that 5 mM CHC
prevented lactate catabolism even though it was taken up.
Furthermore, with addition of 5 mM CHC, there were less 13C-
labeled metabolites present in the media of R3230Ac cells treated
with 5 mM 13C-lactate for 4 h, as expected with inhibition of
lactate uptake at this lactate concentration (Fig 5C).
We next investigated the effects of low (0.1 mM) v. high (5 mM)
CHC concentrations on lactate metabolism at a mid-range
concentration (20 mM). The 13C spectrum of the media only
(blank) did not show evidence of large metabolite peaks, indicating
that background noise was low (Fig S7A). Previously, we have
shown that this concentration of 13C-lactate will be taken up by
R3230Ac cells (Fig 2B). In the 1H and 13C spectra of R3230Ac
cells treated with low (Fig S7B&D) or high (Fig S7C&E) CHC in
the absence of 13C-lactate, no 13C-lactate peaks were evident.
Panels D-G in Figure 9 show 1H spectra for R3230Ac cells after 4
h (Fig 5D&E) or 24 h (Fig 5F&G) exposure to 20 mM 13C-lactate
(-glucose) plus either 0.1 mM CHC (Fig 5D&F) or 5 mM CHC
(Fig 5E&G). No 13C-lactate was evident in the 1H spectra of
R3230Ac cell lysates after 4 h or 24 h incubation with 20 mM
13C-lactate with low or high CHC (Fig 5D-G). Additionally, there
was no evidence of 13C-metabolites in any of the cell lysates (Fig
5D-G). We could not acquire 13C spectra on these samples due to
the low signal. Endogenous lactate (‘‘Len’’) was present in all cell
lysates (Fig 5D-G). Glucose was not included in the media;
therefore, glucose could not be the source of the endogenous
lactate. Formation of endogenous lactate was derived from some
other metabolite present, most likely glutamine or glycogen, as
there have been reports of tumor cells with high glycogen content
[66-70]. The presence of the endogenous lactate peak was evident
after both 4 h and 24 h incubation, indicating that both low and
high CHC partially inhibited endogenous lactate excretion (Fig
5D-G). Endogenous alanine (‘‘Aen’’), which was formed from the
endogenous lactate, was present in cell lysates after 24 h regardless
of the presence of high or low CHC (Fig 5F&G).
In addition to R3230Ac cell lysates, we collected cell media
from these experiments (Fig 5H-K). In each of the 13C spectra, an
abundance of 13C-lactate was seen in the cell media, indicating
that both high and low CHC concentrations effectively inhibited a
majority of 13C-lactate uptake. Peak heights are very similar
regardless of incubation time or CHC concentration; 0.1 mM
CHC was as effective as 5 mM CHC for inhibiting lactate uptake.
There was evidence of 13C-glutamate generation (verified by
HMQC, data not shown) and exportation into the media for each
sample (Fig 5H-K). In the 1H spectra of R3230Ac cell lysates, a
large 13C-glutamate peak was not apparent after 4 h or 24 h;
however, there was evidence of a peak ,2.23 ppm, which
corresponds to 13C-glutamate (Fig 5D-G). This indicates that the
small amount 13C-lactate that was taken up in the presence of
CHC was converted to 13C-glutamate before the 4 h time point.
This would suggest that pyruvate movement into mitochondria by
the MPC was not completely inhibited by 5 mM CHC. The cell
lysate samples do not have resolution comparable to the 13C
spectra, which is why the 13C-glutamate peak is evident in the 13C
spectra of the media but not as apparent in the 1H spectra of the
cell lysates. Furthermore, the 1H spectra of the R3230Ac cell
media showed the presence of endogenous lactate in the media at
relatively similar quantities (Fig S8A-D), which implies that either
concentration of CHC provided incomplete inhibition of endog-
enous lactate exportation. The small peaks in the 1H spectra of the
cell media that may represent 13C-glutamate are not much higher
than background levels, which is why we generated 13C plots (Fig
5H-K).
5 mM CHC significantly increased cell death in MCF7 and
R3230Ac cell lines independent of the presence of
exogenous lactate
MCT1 inhibitors have been given some attention as putative
anti-cancer therapies [16,17,20]. We sought to characterize cell
viability and death responses in MCF7 and R3230Ac cells to high
(5 mM) or low (0.1 mM) CHC in the presence or absence of
glucose 6 high lactate (40 mM). If both the lower and higher
CHC concentration showed significant cell death when lactate was
supplemented, then lactate toxicity would be due to the inability of
the cell to ‘‘detoxify’’ the lactate via biochemical pathways
(generation of alanine and glutamate) or due to factors associated
with prevention of lactate excretion. Of note, it has previously
been shown that cell death is elicited by other MCT1 inhibitors via
the inability of the cell to effectively regulate the lower pHi that
results from lactic acid accumulation from glycolysis [20]. If,
however, cell death was elicited by another mechanism with high
CHC, we would expect that the lower CHC concentration would
not show any cell death. MCF7 cells were chosen as our human
breast cancer model; MDA-MB-231 cells were deemed unfit for
these experiments due to their lack of MCT1 expression. R3230Ac
cells were also used for these studies to maintain consistency with
our in vivo model and to test effects of CHC on an avid lactate-
consuming cell line.
Fig 6A&E shows the percent of total MCF7 and R3230Ac cells
that were viable (Annexin V–/7AAD-) after treatment with high
(5 mM) or low (0.1 mM) CHC concentrations with or without
glucose and/or 40 mM lactate. The control group represents cells
in complete media without lactate or CHC treatment. In MCF7
cells, high CHC + glucose did not significantly change viability.
Without glucose in the media, the percentage of viable cells
dropped from 80% to 56% (#p#0.004 compared to control, Fig
6A). This decrease in viable cells was significant compared to
MCF7 cells treated with 40 mM lactate + glucose ({{p , 0.01, Fig
S3B). High CHC + high lactate and no glucose resulted in 59%
viability. This result was significant compared (*p = 0.003, Fig 6A)
to all groups with no or low CHC, except for the no glucose, no
lactate low CHC group. When a linear regression model was
conducted for MCF7 cells, it was found that CHC concentration
and glucose availability significantly influenced cell viability (p ,
0.0001 and p = 0.001, respectively) but the presence of high lactate
showed no significant changes in cell viability. All high CHC
treatments in R3230Ac cells showed a significantly decreased
percentage of live cells compared to all groups with no or low
CHC (*p , 0.008; Fig 6E). These results show that cell viability
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with this assay is influenced more by CHC concentration and
availability of glucose than the presence of lactate.
Also available from the data set is whether cells died via an
apoptotic pathway (Annexin V+/7-AAD-), loss of membrane
integrity (Annexin V–/7-AAD+) or marked for both (Annexin
V+/7-AAD+) after CHC treatment. Apoptosis was significantly
increased with high CHC in absence of glucose or lactate, but with
those nutrients added back alone or together cells were protected
from apoptosis (#p , 0.05; Fig 6B). R3230Ac cells showed a
significant increase in the percentage of apoptotic cells with high
CHC treatment compared to all no and low CHC treatments (*p
, 0.02, Fig 6F).None of the treatments affected the loss of
membrane integrity of MCF7 or R3230Ac cells (Fig 6C). The
percentage of MCF7 cells marked for both apoptosis and loss of
membrane integrity was significantly increased with all high CHC
treatments (except the high CHC –glucose, -lactate group)
compared to all no or low CHC groups (**p , 0.05, Fig 6D).
There were no significant changes in the percentage of R3230Ac
cells marked for both apoptosis and loss of membrane integrity in
any treatment (Fig 6H).
These results show that R3230Ac cells primarily undergo
apoptosis in response to high CHC and that MCF7 cells stain
positive for both cell death pathways in response to high CHC. In
all the statistical tests conducted, low CHC concentration was not
significantly different from the untreated control or vehicle alone.
The presence or absence of lactate showed no significance in the
statistical models. In summary, the cell death responses elicited
from 5 mM CHC are independent of the presence of exogenous
lactate; therefore, our original hypothesis that CHC would elicit
Figure 5. Inhibition of exogenous lactate uptake and endogenous lactate excretion with addition of CHC. All experiments represented
were carried out in glucose-deprived conditions. 13C spectra of R3230Ac cell lysates incubated for 4 h with 5 mM 13C-lactate without CHC treatment
shows peaks corresponding to lactate (‘‘3’’), alanine (‘‘4’’) and glutamate (‘‘1’’) (A, top). 13C spectra of R3230Ac cell lysates incubated for 4 h with 5 mM
13C-lactate with 5 mM CHC treatment show no peaks corresponding to lactate or metabolites (A, bottom). 13C spectra of R3230Ac cell lysates
incubated for 4 h and 24 h with 40 mM 13C-lactate + 5 mM CHC shows a peak corresponding to lactate (arrow) but no other metabolites (B). 13C
spectra of R3230Ac cell media incubated with 5 mM 13C-lactate for 4 h shows peaks corresponding to alanine and glutamate without CHC treatment
(C, top); metabolite peaks are absent or smaller with 5 mM CHC (C, bottom). 1H spectra of R3230Ac cell lysate with the following treatments: 20 mM
13C-lactate + 0.1 mM CHC for 4 h (D) 20 mM 13C-lactate + 5 mM CHC for 4 h (E), 20 mM 13C-lactate + 0.1 mM CHC for 24 h (F), 20 mM 13C-lactate +
5 mM CHC for 24 h (G). 13C spectra of R3230Ac cell media with the following treatments: 20 mM 13C-lactate + 0.1 mM CHC for 4 h (H) 20 mM 13C-
lactate + 5 mM CHC for 4 h (I), 20 mM 13C-lactate + 0.1 mM CHC for 24 h (J), 20 mM 13C-lactate + 5 mM CHC for 24 h (K).Endogenous lactate = green
‘‘Len’’, endogenous alanine = orange ‘‘Aen’’,
13C-lactate = dark green ‘‘13C-L’’, 13C-glutamate = blue ‘‘13G’’, DMSO = brown ‘‘D’’
doi:10.1371/journal.pone.0075154.g005
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cell death in lactate-treated, glucose-deprived cells due to the
inhibition of lactate uptake and utilization was incorrect.
Exogenous lactate is taken up but not catabolized in
hypoxic R3230Ac cells
Figure 7C&D showed that lactate uptake occurs primarily in
aerobic regions of R3230Ac tumors. It is known that hypoxic cells
upregulate glycolysis, resulting in higher lactate production [71].
This glycolytically-derived lactate will then be exported from the
cell, resulting in high lactate accumulation in hypoxic areas of the
tumor [10]. Therefore we hypothesized that hypoxic cells would
take up exogenous lactate, but would not be able to catabolize it.
The 13C spectra of glucose-deprived, 13C-lactate-treated R3230Ac
cells show uptake and utilization of 13C-lactate, with many labeled
metabolites present after 12 h. In glucose-deprived and hypoxic
conditions, after 12 h incubation with 40 mM 13C-lactate, the 13C
spectra of R3230Ac cell lysates show evidence of the lactate peak
but no corresponding labeled metabolites. This indicates that
although hypoxic cells can take up lactate, it is cannot be utilized
for metabolite generation.
Figure 6. 24 h exposure to 5 mM CHC significantly decreases cell viability and increases cell death responses in MCF7 and R3230Ac
cells independent of addition of high lactate. Cell viability as measured by Annexin V –/7-AAD – labeling (n = 3) in MCF and R3230Ac cells
treated with high (5 mM) or low (0.1 mM) CHC with and without glucose (no lactate) and with 40 mM lactate (with and without glucose). Viable
MCF7 cells show significant decreases with 5 mM CHC (A, #p#0.004 compared to control (no CHC, no lactate + glucose), ``p , 0.01 compared to
40 mM lactate-treated MCF7 cells, *p = 0.003 compared to all no CHC and low CHC groups). Percentage of apoptotic (Annexin V+/7-AAD-)
MCF7 cells show significant increases with the –glucose-lactate+high CHC treatment and the +glucose+lactate+high CHC treatment (#p ,
0.05) and between the –glucose–lactate+high CHC group and 40 mM lactate treatments without CHC (+ or – glucose) ({p , 0.05, B). Percentage
of MCF7 cells with loss of membrane integrity (Annexin V–/7-AAD+) show no significant differences with CHC treatment (C). Percentage of
MCF7 cells marked for both cell death pathways (Annexin V+/7-AAD+) show significant increases with 5 mM CHC compared to the no CHC
and low CHC groups (**p , 0.05, D). Percentage of viable R3230Ac cells show significant decreases with 5 mM CHC compared all no CHC and
low CHC groups (*p , 0.008, E). Percentage of apoptotic (Annexin V+/7-AAD-) R3230Ac cells show significant increases with 5 mM CHC
compared to compared to no CHC and low CHC groups (*p , 0.02, F). Percentage of R3230Ac cells marked for loss of membrane integrity
(Annexin V–/7-AAD+) show no significant differences except–glucose-lactate+high CHC treatment (`p , 0.05, G). Percentage of R3230Ac cells
marked for both cell death pathways (Annexin V+/7-AAD+) show no significant changes with any treatment (H). Results analyzed with One-
Way ANOVA and Bonferroni/Dunn post-hoc tests.
doi:10.1371/journal.pone.0075154.g006
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Discussion
Our study shows that breast cancer cells tolerated and
catabolized lactate at concentrations found in human breast
cancer. Breast cancer cell lines showed different rates of lactate
uptake and generation of similar catabolites (glutamate and
alanine) in vitro and in vivo. In vivo, uptake of lactate occurred
more quickly than uptake of glucose in tumor tissue, and this
uptake coincided with perfused (rather than hypoxic areas) of the
tumor. In vitro, hypoxic breast cancer cells did not show catabolism
of lactate. Taken together, our study strongly supports one side of
the metabolic symbiont model: the assertion that aerobic breast
cancer cells can tolerate and metabolize lactate. Our autoradiog-
raphy data provide further evidence that the metabolic symbiont
model may operate in some solid tumors. Manipulation of lactate
uptake and catabolism was accomplished with use of CHC, but
higher concentrations of CHC killed breast cancer cells in a
manner that was not dependent upon the presence of lactate. This
suggests that cytotoxic activity of CHC is unpaired from lactate
metabolism in our model.
In the past we have shown that lactate can be used as a substrate
for aerobic cancer cells and that MCT1 and MCT4 expression
correlate with the ability of certain cancer cell lines to consume
lactate [17]. Here, we showed that cellular responses to exogenous
lactate varied depending upon cell type and glucose availability,
but, overall, at concentrations seen in human breast cancer, lactate
was well-tolerated (Figs S1 & S2) and catabolized (Figs 3–5). Cell
lines that consume more lactate ( ‘‘high lactate-consumers’’)
showed less of a reliance on glucose for cell growth compared to
cell lines that consumed less lactate (‘‘low lactate-consumers’’) (Fig
5, S5, 8). The R3230Ac tumors demonstrated a significantly
higher kinetic uptake rate for lactate than for glucose (Fig 3) and
showed no changes in cell survival with glucose-deprivation (Fig
S1D & S2D), providing additional evidence for a high lactate-
consuming phenotype.
In all of the experiments conducted, the concentration of
glutamine was not altered, and therefore present at concentrations
of the manufacturer’s supplementation (4 mM). Glutamine has
been shown to be an important metabolite for growth of cancer
cell lines in culture [67]; therefore, we chose to not remove it.
Previous reports indicate that the contribution of glutamine to
lactate formation is approximately 7–13%, depending on the
growth phase and other metabolites in the culture media [66].
While glutamine may contribute to a small amount of lactate
formation [66], the major metabolite responsible for lactate
formation is glucose. The significance of convergent pathways of
glutamine and lactate metabolism may warrant future study,
especially in tumor cells that may demonstrate less of a
dependence on glucose as a primary substrate.
For lactate to act as an energy substrate, it needs to be converted
to pyruvate, enter the mitochondria and go through oxidative
phosphorylation. Through use of labeled lactate, it has been
previously found that lactate completes the course of oxidative
phosphorylation, as shown by generation of labeled CO2 [56,72].
Likewise, we found that R3230Ac cells significantly increased
oxygen consumption with increasing lactate concentrations (Fig
2E). Another strong indication of the use of labeled lactate as a
substrate to enter the TCA cycle that we found in our study was
the appearance of labeled glutamate in the cell lysates and media
of all cell lines tested (Figs 5–8). The most straight-forward
pathway for 13C-glutamate formation is: 13C-L-lactate « 13C-
pyruvate R R TCA cycle partial completion R 13C- a –
ketoglutarate R 13C-glutamate. We also identified alanine peaks
after adminstration of 13C-L-lactate. Labeled alanine formation
occurs through: 13C-L-lactate « 13C-pyruvate + glutamate «
13C-alanine + a-ketoglutarate. Alanine and glutamate (whether
labeled or endogenous) can participate in the reaction catalyzed by
alanine aminotransferase (a -ketoglutarate + alanine «glutamate
+ pyruvate). While this seems to only shift the balance of lactate
catabolites, this reaction may serve to temporarily alleviate
nitrogen stress in the cell by transferring it to glutamate. When
alanine is formed in other organs, particularly in skeletal muscle, it
can be shuttled to the liver to participate in the Alanine Cycle
(similar to the Cori Cycle) [73]. Alanine generated in the tumor is
unlikely to participate in the Alanine Cycle, as the diffusion of
metabolites to a blood supply and transport is limited by vessel
arrangement and efficiency, respectively [74]. The alanine
generated may be used for anabolic purposes by the tumor, but
it is also possible that alanine participates in futile metabolic cycles.
The metabolic fate of these lactate catabolites would be an
interesting avenue of further research, and future studies could
determine whether inhibiting lactate catabolism pathways in
tumors may provide another therapeutic option.
No prior reports have compared the consumption of lactate to
that of glucose in vivo. We showed that the R3230Ac tumor
consumes glucose and lactate simultaneously in vivo, converting
lactate to alanine and glutamate. Our kinetic data support avid
uptake of 14C-lactate by the tumor in vivo, with uptake rate
constants that are higher than that of glucose. These results suggest
that lactate may be an important substrate for the R3230Ac tumor
line. Second, we demonstrated that lactate was taken-up most
preferentially in oxygenated tumor regions (Fig 4). In prior studies,
we demonstrated that lactate accumulation was highest in
perinecrotic hypoxic tumor regions of the R3230Ac tumor [10].
These results strongly suggest that at least part of the lactate that is
produced by hypoxic tumor regions may diffuse down its own
concentration gradient, toward better perfused aerobic cells, which
can then take it up via the MCT transporters and utilize it. In
other work by our group we have indeed found this to be the case
[17], which leads to preferential death of hypoxic tumor cells,
substantial growth delay and increased radiation response. Our in
vivo results support this suggestion that there may be a cooperative
relationship between different cells within the R3230Ac tumor.
Recently, it has been reported that lactate uptake in endothelial
cells contributes to increased angiogenesis and HIF-1a expression
[64,75]. The ability of tumor stroma to consume lactate supports
Figure 7. Hypoxic R3230Ac cells take up 13C-lactate. Treatment
with 40 mM 13C-lactate in glucose-deprived, normoxic R3230Ac cancer
cells result in lactate uptake and metabolism after 12 h (A). Under
hypoxic conditions, evidence of lactate uptake (arrow) but no additional
labeled metabolites can be seen in the cell lysates after 12 h (B). Arrow:
13C-methyl lactate.
doi:10.1371/journal.pone.0075154.g007
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Figure 8. Summary diagram of lactate metabolism in high lactate-consumers vs. low lactate-consumers. The blue gradient represents
oxygen diffusion. The cell on the left is hypoxic; the cells on the right are aerobic. Arrow colors correspond to substrates, and arrow size corresponds
to relative amount. Hypoxic tumor cells take up glucose (gray ‘‘Glc’’) and produce lactate (dark green ‘‘L’’), leading to higher concentrations of
lactate. Lactate may be taken up by the hypoxic tumor cells, but it is not catabolized. Aerobic tumor cells that are high lactate-consumers and likely
express high MCT1/low MCT4 can take up lactate and catabolize it to alanine (orange ‘‘A’’) and glutamate (blue ‘‘G’’), which will be exported from the
cell. With the aerobic high lactate-consumer cell consuming lactate, more glucose can potentially be spared for hypoxic tumor cell use, potentially
conferring a survival advantage. Aerobic tumor cells that are low lactate-consumers and likely express low MCT1/high MCT4 take up less lactate than
the high lactate-consumers, consequently producing and exporting less alanine and glutamate. Low lactate-consumers utilize more glucose, which
will not allow glucose to reach the hypoxic tumor cells (A). One proposed strategy for starving hypoxic tumor cells of glucose in a high lactate-
consuming tumor is to treat with a MCT1- inhibitor, like CHC. CHC prevents lactate uptake and catabolism in cells, forcing the aerobic high lactate-
consumer to use glucose, which starves the hypoxic tumor cell of glucose. Lactate transport out of hypoxic cells is also inhibited, which would also
lead to hypoxic cell death (B).
doi:10.1371/journal.pone.0075154.g008
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tumor growth. Additionally, other groups have shown that tumor-
associated fibroblasts undergo aerobic glycolysis, producing
lactate, which can then be utilized by tumor cells; this has been
termed the ‘‘Reverse Warburg Effect’’ [76–79]. In vitro, we
observed production of both alanine and glutamate in R3230Ac
cells as well as normal human breast epithelial cells and human
breast cancer cell lines after administration of 13C-lactate. The fact
that lactate utilization was seen in human breast cancer as well
warrants further investigation of their lactate-consuming ability in
vivo, as the lactate-consuming phenotype of particular tumors may
influence treatment strategies.
Therapeutically targeting lactate metabolism in tumor cells has
been proposed [16,17,64,80] and is currently being evaluated in
Phase I/II clinical trials [81]. Previously, inhibition of MCT1,
specifically with CHC, was used to block lactate uptake in more
oxidative cells, thereby starving their more hypoxic neighbors of
glucose [17]. While these results are encouraging, it is well
documented that CHC does not only inhibit lactate transport.
MCTs transport many monocarboxylates. Though each subtype
has a different affinity for particular monocarboxylates, the most
widely-expressed and well-characterized subtypes (MCT1, 2 and
4) are capable of transporting lactate, pyruvate, butyrate and
ketone bodies [14]. Inhibiting the transporter will theoretically
prevent trafficking of each of these monocarboxylates. Diers et al.
recently reported that 0.5 mM CHC treatment prevented
pyruvate uptake and inhibited mitochondrial respiration in breast
cancer cells [82]. At the CHC concentrations used in our study
(0.1 and 5 mM), it is likely that pyruvate (in addition to lactate)
transport was also impaired.
Despite the ability of 5 mM CHC to inhibit lactate catabolism
and export at 40 mM concentrations (Fig 5B), we found that
40 mM lactate was not cytotoxic to MC7 or R3230Ac cells (Fig 6).
High CHC elicited significant cell death independent of addition
of exogenous lactate, indicating that off-target effects are
responsible for cancer cell death at this concentration of CHC.
These results suggest that CHC may not be the best therapeutic
MCT1 inhibitor. Other MCT1 inhibitors have elicited cancer cell
death via decreased pHi with treatment [20]. It is important to also
address the potential toxicity with MCT1 inhibition in normal
tissue as well as in other diseases that show high lactate levels, such
as meningitis or sepsis [83,84]. Encouragingly, in a recent study,
we found that mice treated with CHC showed no morbidity [85].
Targeting tumor metabolism has been proposed as an anti-
cancer therapy, specifically, MCT1 inhibition has received
attention in recent years [16,17,20,64,80,81]. Our study supports
the rationale that it is important to first know the metabolic
phenotype of the individual tumor before administering metabolic
intervention. With all breast cell lines tested, we saw tolerance of
lactate at concentrations relevant to breast cancer. Our results
demonstrate two different lactate-consuming phenotypes: high
lactate-consumers (R3230Ac and MCF7) and low lactate-consum-
ers (MDA-MB-231) (Fig 8). We showed that lactate consumption
and glucose dependence differ between the lactate-consuming
phenotypes and that catabolite generation from extracellular
lactate was not equal in relative rates or amounts, with low lactate-
consumers (MDA-MB-231 cells) showing smaller peaks of alanine
and glutamate compared to high lactate-consumers (R3230Ac or
MCF7 cells) (Fig 8). Inhibiting lactate uptake in aerobic R3230Ac
cells may starve their hypoxic neighbors (metabolic symbiont);
however, this model needs to be studied in more detail in vivo to
assess its overall influence on tumor survival. Our studies also
indicate that tumors that behave similar to MDA-MB-231 cells
(lacking MCT1 expression and/or showing low lactate consump-
tion) may not be a good candidate for manipulation of lactate
pathways. Given these inherent differences, a single approach for
metabolism manipulation is not appropriate; therapeutically
targeting tumor metabolism would need to be tailored to
particular metabolic phenotypes.
In clinical studies, it has been found that lactate accumulation is
an indicator of shorter metastasis-free and overall patient survival
[2,34,35,38,39,46]. A recent study measuring lactate accumulation
and spatial distribution in prostate cancer compared the aggres-
sive, anaplastic, fast-growing Dunning R3327-AT to the parental,
well-differentiated, slow-growing Dunning R3327-H in animal
models [86]. Similar to the findings in human solid tumors, the
more aggressive AT tumor line showed significantly more lactate
accumulation and necrosis, specifically in the tumor core [86]. Not
surprisingly, the same conclusion from human and animal studies
emerges: lactate accumulation is a reliable indicator of tumor
aggressiveness, associated with fast growth and necrosis within a
solid tumor [10,22,35,38,39,47,86]. The topic of lactate utilization
is investigated comparatively less, and the importance of the
lactate-consuming phenotype is currently unknown. Our study has
investigated lactate uptake and catabolism in three breast cancer
cell lines and two normal cell lines in vitro and in one breast tumor
model in vivo. Comparing lactate consumption in benign and
malignant tumor models is the next step in elucidating the
importance of lactate consumption to tumor survival and/or
aggressiveness.
Lactate accumulation and utilization are two sides of the same
coin. The unanswered questions regarding the ability of the tumor
to utilize lactate are: 1. Is it an indicator of a less aggressive tumor
or is the ability to consume lactate a survival advantage? (Are these
questions mutually exclusive?) 2. Can we effectively alter (and
sustain the alteration of) the lactate-consuming phenotype of a
tumor through manipulation of metabolic pathways? Recently
there has been increasing interest in targeting lactate metabolism
in tumors. A greater understanding of the complex and dynamic
metabolic pathways that operate in tumors provide more avenues
for tailored treatments.
Methods
Lactate, CHC and Cell Culture
Sodium L-lactate (C3H5NaO3) was purchased from Sigma-
Aldrich (St. Louis, MO, USA). All sodium lactate concentrations
for cell treatments were made by diluting the powder in
appropriate cell media. Solutions were discarded after 2 weeks.
For NMR, sodium L-lacate-3-13C solution (45–55% w/w in H2O)
99 atom % 13C was acquired from Isotec (Sigma, St. Louis, MO).
Alpha-cyano-4-hydroxy-cinnamate (CHC) powder was acquired
from Sigma (St. Louis, MO) and dissolved in DMSO to create
1 M and 100 mM stock solutions. The stock solution was passed
through a 0.22 mm filter prior to dilution in treatment media to
acquire concentrations equal to 0.1, 1, 2.5, 4, or 5 mM.
Cell lines used include MCF7 (ER+ human breast adenocar-
cinoma), MDA-MB-231 (triple negative human breast adenocar-
cinoma), HMEC (human mammary epithelial cells), and R3230Ac
(rat mammary carcinoma. Cells were maintained in 37uC,
5%CO2, 20% O2 in a Forma Scientific (Marietta, OH) incubator.
All cell lines were acquired through Duke University’s Cell Culture
Facility and from ATCC (Manassas, VA), except HMEC, which
were acquired from Clonetics (Switzerland). HMEC cells were
cultured in MEBM media from Lonza/Clonetics (Switzerland)
with added supplements (‘‘MEGM media’’, SingleHQuotsH: 2 mL
BPE, 0.5 mL hEGF, 0.5 mL insulin, 0.5 mL hydrocortisone,
0.5 mL GA-1000). All other cell lines were cultured high glucose
DMEM (Gibco) +10% FBS + 1% antibiotic/antimycotic. For
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glucose deprivation experiments, DMEM without glucose or
sodium pyruvate was used (Gibco) +10% FBS + 1% antibiotic/
antimycotic. In all experiments, L-glutamine was present in
DMEM media at the manufacturer’s concentration; glutamine
was never omitted or altered. Hypoxia experiments were carried
out in the Invivo2 500 hypoxia chamber (Ruskinn Technology
Ltd, Pencoed, Bridgend, UK). Gas mixtures were 0.5% O2, 5%
CO2, and 94.5% N2.
In vitro sodium lactate measurements in cell media
Unlabeled sodium lactate was measured in cell media with the
commercially available first-generation (discontinued in favor of
the second-generation) Lactate Pro measuring device, which has a
reliable measuring range between 0.8 – 23 mM. Cells were plated
at a known density and allowed to reach 60% confluency before
the beginning of the experiment. At this time, the cell media was
changed from high glucose DMEM (+ 10% FBS) to glucose-free
DMEM (+ 10% FBS). Time zero was designated at the addition of
20 mM exogenous lactate. Lactate measurements were taken at
times 0, 1, 2, 4, 8, 12, 24, 48, 72, 96 and 120 h. The media was not
changed over the entire 5-day period. Lactate measurements were
conducted as follows: 100 mL of cell media was placed on the
Lactate Pro measuring strips that were then inserted into the
Lactate Pro device. A standard curve of known lactate concen-
trations was performed, and the device was calibrated with a
known lactate concentration prior to experimental measurements
(SEM = 6 0.34 mM). At the end of the experiment, cells were
counted. Five independent experiments were conducted. Overall
mean lactate concentration decreases in the cell media and the
amount of lactate consumed per cell were calculated. A linear
regression analysis was conducted on the lactate measurements.
Rate coefficients were determined after controlling for the time
and batch effects.
Cell Growth in vitro in lactate media vs. glucose media
MCF7 and MDA-MB-231 cells were plated at equal densities
and allowed to reach 60% confluency before the beginning of the
experiment. At this time, the cell media was changed from high
glucose DMEM (+ 10% FBS) to either glucose-free DMEM
(+ 10% FBS) with supplemented 20 mM lactate or high-glucose
DMEM (+10% FBS). Cells were allowed to grow for 5 days before
being harvested and counted.
Cryosectioning, Bioluminescence and Image analysis
Collection of human tissue LABC biopsies was approved by
Duke University Health System Institutional Review Board (IRB),
and patient samples were de-identified before acquisition for
cryosectioning. All patients provided written informed consent to
participate in the study. The Duke University Institutional Review
Board approved the protocol and the informed consent procedure.
Cryosectioning of human LABC biopsies was performed on the
Leica CM1850 Cryostat (Leica, Wetzlar, Germany) at –30uC.
Sections for immunohistochemistry were cut at 10 microns and
mounted on Superfrost Plus Micro Slides (VWR, West Chester,
PA), and sections for metabolite bioluminescence were cut at 20
microns and mounted on 22640 micro cover glass (VWR)
coverslips.
Bioluminescence techniques were carried out as previously
described [10,36,37,87]. Briefly, 20 micron-thick frozen sections
were exposed to a luciferase-bound LDH enzyme mixture and
quickly placed in the dark under a light microscope camera.
Luciferase signal was acquired for 10 seconds. Known lactate
standards were run in parallel. All 16-bit images were imported to
Image J for pixel grayscale intensity analysis; a standard curve was
generated from the pixel values from the lactate standards. Lactate
values were extrapolated from the standard curve. Three to four
sections were measured per sample.
Protein extraction and Western Blots
Protein extraction was carried out on ice using complete
RadioImmuno Precipitation Assay (RIPA) lysis buffer + 0.1%
protease inhibitor cocktail (BioRad, Hercules, CA). Concentra-
tions of total protein were measured with DCTM Protein Assay
from BioRad (Hercules, CA). For MCT1 Western blots, 15–50 ug
per sample were loaded into wells. Proteins were separated by
SDS-PAGE in a 12% gel (Bio-Rad, Hercules, CA), then
transferred to a polyvinylidene fluoride (PDVF) membrane (Bio-
Rad). Membranes were blocked for one hour in 5% non-fat, dry
milk reconstituted in TBST. MCT1 rabbit anti-human IgG
primary antibody (Millipore, Billerica, MA) and MCT4 rabbit
(recognizes human, mouse and rat) IgG primary antibody (Santa
Cruz Biotechnology, Dallas, TX, USA) were used, diluted 1:1000
in TBST and incubated in 4uC overnight. The secondary goat
anti-rabbit IgG horseradish peroxidase-linked antibody (Jackson
ImmunoResearch Labs, West Grove, PA) was diluted 1:2000 in
TBST and incubated in room temperature for one hour.
SuperSignalH West Pico Luminol/Enhancer Solution (Pierce,
Rockford, IL) was used to detect bands before exposure to Kodak
film (Rochester, NY). Pan-actin controls were run in accordance.
Measurement of 13C lactate uptake using NMR: in vitro
studies
Tissue culture dishes (15cm diameter) were plated at cell
densities between 2 and 36106 cells. After allowing 24 h for cells to
attach, or after achieving 80% confluency, cells were washed twice
with 1x DPBS and then treated with either high-glucose DMEM
(untreated control), no glucose (and no pyruvate) DMEM + 12C
(unlabeled) lactate (unlabeled control) or 3-13C-lactate (Isotec,
Sigma, St. Louis, MO). Cells were exposed to 10–40 mM 3-13C-
lactate in normoxic or hypoxic conditions for 4, 12 or 24 h. At the
end of the incubation period, 1 mL of media was collected and
immediately frozen at –80uC. These media samples were used to
acquire 1H, 13C and HMQC spectra of exported metabolites.
Cells were washed twice with DPBS. For metabolite extraction,
1 mL of 0.9 M perchloric acid, diluted 1:10 in diH2O, was added
to each dish, and cells were scraped. The samples were centrifuged
at 12,000 RPM for 10 minutes to pellet cell debris and precipitate.
Supernatant was transferred to a fresh tube, and this was used for
NMR on cell lysates.
For NMR readings, 600 mL total volume was used. For cell
lysates, 450 mL of the perchloric acid cell lysate, 100 mL DPBS and
50 mL D2O were added to the NMR tube. For media samples,
550 mL media and 50 uL D2O were mixed. Tubes were capped
and placed in the 500 MHz Varian Inova NMR spectrometer
(Palo Alto, CA). The samples were measured with the High
Resolution NMR Spectroscopy shared resource of the Duke
Cancer Institute. VnmrJ Software (Varian) was used to acquire
and analyze the spectra. All samples were tuned and shimmed
before data acquisition. 13C-NMR spectra were acquired at
125.7 MHz with a Varian 500 MHz spectrometer equipped with
a 5 mm broad-brand probe. Specifications were: a 45u flip angle,
0.8 s interpulse delay, and a 1.334 s acquisition time. All proton
spectra were measured at 500 MHz.
Annexin V/7-AAD staining
Cells were seeded in 6-well plates and allowed to reach 70%
confluence before 24 h lactate treatment in high glucose
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DMEM+10% FBS + 1% antibiotic/antimycotic or glucose-free
and sodium pyruvate-free DMEM+10% FBS + 1% antibiotic/
antimycotic. Lactate concentrations used were 0–40 mM. For
MCF7 and R3230Ac cells, treatment groups also included high
(5 mM) or low (0.1 mM) CHC concentrations in the context of
available glucose or glucose-deprivation and with or without
40 mM lactate. After treatment, media and cells were collected
and centrifuged. Cells were resuspended in PBS and centrifuged.
Live (unfixed) cells were then resuspended in 100 mL of 1X
Annexin Binding Buffer (BD Pharmigen, San Diego, CA) in a
round-bottom polystyrene tube (BD FalconTM, Bedford, MA).
5 mL of PE-labeled Annexin V (BD Pharmigen, San Diego, CA)
and 5 mL 7-AAD (BD Pharmigen, San Diego, CA) were added to
each experimental tube. Samples were incubated in the dark for
15 minutes and tapped gently to mix. 300 mL of Annexin Binding
Buffer was added to each tube. Tubes were covered with
aluminum foil and transported to Duke Cancer Institute Flow
Cytometry Shared Facility. All sample data for cell cycle were
analyzed with BD Calibur Flow Cytometer (GMI, Ramsey, MN).
10,000 events were acquired and the percentage of total cells with
positive staining was reported. Error bars represent 6 SEM.
Results were analyzed with One-Way ANOVA and post-hoc tests.
Animals
Female Fischer 344 rats (n = 9 for 14C-glucose experiments,
n = 3 for 14C-lactate experiments) were implanted subcutaneously
in dorsal mammary fat pad with 1–2 mm pieces of R3230Ac
mammary carcinoma tissue extracted from a tumor from a donor
animal. Experiments were conducted when tumors reached 1–
2 cm in diameter. Prior to the start of the experiment rats were
fasted for four hours [88]. Rats were anesthetized with isofluorane
gas. Once anesthetized, the rat was placed on a heating pad (K-
module, Baxter Healthcare, Valencia, CA) to maintain body
temperature of 37uC. The heating pad and rat were contained
within a light-tight box so that the light detected by the scintillation
probes came only from interaction with the 14C-electrons. The
femoral artery and vein were cannulated for monitoring blood
pressure with a Digital Manometer (Fiber optic Sensor Technol-
ogies Inc., Ann Arbor MI) and infusion of 14C-glucose, 14C-lactate
or 13C-lactate (in vivo NMR experiments).
This study was approved by Duke University’s Institutional
Animal Care and Use Committee (IACUC), and the experiments
were carried out in strict adherence to their guidelines and
recommendations. Duke University maintains an animal program
that is registered with the USDA (Permit # 83), assured through
the NIH/PHS (Permit # A3195-01), and accredited with
AAALAC, International (Permit # 363). All surgery was
performed under isofluorane anesthesia, and all efforts were made
to minimize suffering.
14C scintillation Probe Calibration
The purpose of these studies was to determine the kinetics of
14C-labeled lactate and 14C-labeled glucose uptake and excretion
from tumor, compared with normal tissue. The detection device
and scintillation probes were provided by Sicel Technologies Inc.,
Durham, NC. The apparatus consisted of fiber-optic scintillation
probes connected to photomultiplier tubes (PMTs) and a
computer. The electrons emitted by 14C were detected by the
fiber-optic probes, and this interaction of the electrons with the
probe creates photons that are detected by the PMTs. In principle,
the apparatus works like a scintillation counter. For each
experiment two probes were used (tumor and SQ of the flank).
Tumor dimensions were measured and the length of probe to be
inserted into the tumor was determined (6–10 mm), based on
tumor size. The length of probe inserted into the subcutaneous
position was always 20 mm. Each individual probe was calibrated
using a 14C-lactate solution of known concentration (mCi/mL)
with the probe being immersed in the solution at the same depth
as the in vivo tumor measurement. This calibration was done to
normalize for variability between probes and the insertion length
of probe used in different tumors. Prior to the start of the probe
calibration, the PMTs were turned on to check for light leakage
into the device. If there was no light leakage measurements were
recorded every two minutes for approximately three hours. After
the calibration was finished, probes were cleaned with alcohol.
Pharmacokinetics of 14C radioisotope in vivo
For each experiment, one probe was placed in the tumor and a
second in SQ tissue. After the cover of the light-tight box was
positioned a 45–60 minute probe stabilization period was allowed
to elapse prior to injection of the 14C-labeled substrate. During this
time and for the rest of the experiment the rat was continually
monitored. Blood pressure and heart rate were monitored using
the Digital Manometer (Fiber optic Sensor Technologies Inc., Ann
Arbor MI). Body temperature was measured using a rectal probe.
Breathing rate and depth of anesthesia were monitored by
observation via an infrared camera inside the box connected to
a small television.
After stabilization, 100 mCi of 14C-glucose (1 mCi/ml) or
50 mCi of 14C-lactate (1 mCi/ml) was infused at a rate of
0.1 mL/minute and signals were collected for approximately
three hours. Time zero was defined as the start of the infusion.
Blood samples (300 mL –500 mL) were taken at 0, 4, 7, 10, 15, 25,
30, 60, 100, and 160 minutes from the artery cannula using
heparinized syringes. The samples were centrifuged (40,000 RPM,
15 min) and the plasma removed and weighed. 7 mL of Ultima
Gold scintillation cocktail (Perkin Elmer Life and Analytical
Sciences Inc., Boston MA) was added to each vial. Samples were
measured in a Packard Tri-Carb 1500 Liquid Scintillation
Counter (Perkin Elmer Life and Analytical Sciences Inc., Boston
MA). Counts per minute (CPM) were converted to Disintegrations
per Minute (DPM) by the scintillation counter by using set of 14C-
standards at known concentrations. The scintillation counter uses
the standards to create a quench curve allowing for the conversion
of CPMs to DPMs. Concentration (mCi/g) for each sample was
calculated by dividing the number of mCis in the plasma by plasma
weight. The blood activity data were then normalized to dose/
body weight.
Compartmental model
14C-glucose and 14C-lactate uptake data were analyzed using
compartmental modeling. A 3-compartmental model was used for
14C-glucose and 14C-lactate data. The following parameters were
defined in the model: Cp = glucose or lactate concentration in the
blood compartment, Ci = glucose or lactate concentration in the
tumor compartment, and Cs = glucose or lactate concentration in
the subcutaneous compartment. Rates: k0 = clearance by other
tissues, k1 = transfer rate of glucose or lactate from blood into
tumor, k2 = transfer rate out of tumor, k3 = transfer rate into the
subcutaneous tissue, and k4 = transfer rate out of the
subcutaneous tissue. The details of the model are described in
the supplemental material (Fig S1).
13C lactate NMR from extracted R3230Ac tumors
For in vivo NMR experiments, rats were handled in a similar
manner. The femoral artery and vein were cannulated for
monitoring blood pressure with Digital Manometer (Fiber optic
Sensor Technologies Inc., Ann Arbor MI) and infusion of 13C-
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lactate, respectively. 1 mL of 100 mM 13C-lactate was infused
intravenously over 10 minutes. Time zero was considered to be the
start of the infusion. At baseline, 15, 30, 45, 60 and 90 minutes rats
were sacrificed and the tumor, liver and brain removed within 60 s
and snap-frozen in liquid nitrogen. The frozen tissues were pulverized
with a mortar and pestle under liquid nitrogen. 2 mL total of 0.9 M
perchloric acid was added to the pulverized tissue. Once thawed at
4uC, the extract was homogenized and neutralized with KOH. Salt
was removed by centrifugation and the supernatant was frozen and
lyophilized. Each experiment was repeated three times.
The lyophilized samples were dissolved in 630 mL phosphate
buffer and 70 mL (10%) deuterium. 15 mL of dioxane was added to
each sample as an internal standard. 13C-NMR spectra were
acquired at 125.7 MHz with a Varian 500 MHz spectrometer
equipped with a 5 mm broad-brand probe. A 45u flip angle, 0.8 s
interpulse delay, and a 1.334 s acquisition time were used for all
experiments. Standards of glucose, G6P, glutamate, lactate, and
alanine at concentrations of 1 mM, 5 mM, and 10 mM with
dioxane as an internal standard were also run. The standards were
used to create standard curves, which were used to convert peak
heights of the different metabolites in each spectrum to
concentrations. Additionally the data were analyzed, comparing
ratios of different metabolites within a spectrum. The ratios were
obtained from peak heights of metabolites.
Autoradiography
14C-lactate autoradiography was used to study the spatial
distribution of lactate uptake. Athymic nude mice transplanted
with R3230Ac tumors were infused with twomCi of 14C-lactate.
The hypoxia marker drug, pimonidazole (60 mg/kg i.p.), was
injected. Thirty minutes later, Hoechst-33342 was administered
intravenously as a perfusion marker dye (10 mg/ml, 0.05 ml).
Two minutes later, tissues were harvested and snap-frozen. A
portion of the frozen tumor was cryosectioned at 14 mm thickness
for autoradiography, Hoechst staining and pimonidazole staining.
Electronic autoradiography was performed with a storage
phosphor system (Packard Bioscience, Downers Grove, IL).
Sections were loaded onto a storage phosphor screen and exposed
for 3 weeks. A slide with 14C-standards was also placed on the
screen for quantification. The screen was then processed and read
in the phosphor system to visualize the distribution of 14C-lactate.
Intensity level obtained from the reader was converted to activity,
based on the standard slides.
Immunohistochemistry staining
To co-localize the lactate uptake and oxygenation status in
tumor, immunostaining of hypoxia with pimonidazole was
performed on tumor sections. Tumor cryosections were fixed
with paraformaldehyde (room temperature, 30 minutes), blocked,
and then stained with mouse anti-pimonidazole antibody labeled
with Alexa FluorH 555 (excitation wavelength = 580 nm). Slides
were imaged using a microscope equipped with automatic
scanning stage for whole slide scan. Hoechst-33342 (excitation
wavelength = 460 nm) images were also obtained by scanning
slide with blue filter.
Autoradiography, hypoxia, and perfusion images were regis-
tered and overlaid to show the relationship between lactate uptake,
hypoxia, and perfusion.
Measurement of oxygen consumption in confluent cells
using a Seahorse XF24 extracellular flux analyzer
R3230Ac cells, cultured in high glucose DMEM with 10%
serum and 1% antibiotics were washed, trypsinized, counted, and
seeded in Seahorse XF24 cell culture plates at 60,000 cells per well
in growth medium. According to the manufacturer’s instructions,
cells were allowed to adhere for 2 hours before growth medium
was added to a total volume of 250 mL. Cells were allowed to grow
overnight at 37uC, 5% CO2. On the day of the experiment, cells
were washed and mounted with warm XF assay medium, and
incubated for 60 min at 37uC without CO2 before starting the
experiment. During the experiment, Na-Lac was added to each
well at varying concentrations (diluted in water) by the automatic
dispenser to equal a total volume of 75 mL. Three independent
experiments were carried out in triplicate. Results are represented
as percent of baseline respiration rate 4 minutes after addition of
lactate.
Statistics
Student’s T-test was used to evaluate mean lactate concentra-
tion differences between duplicate LABC biopsies from the same
patient. Student’s T-test was also used to evaluate differences in: 1.
Oxygen consumption in lactate-treated cell in Figure 2, 2. Cell
number between MCF7 and MDA-MB-231 cells after five days of
lactate treatment in Figure 4, and 3. Cell number between glucose-
free, lactate supplemented media and high-glucose, lactate-free
media in Figure S5. A linear regression analysis was applied to
cellular lactate consumption data in Figure 4. One-way analysis of
variance (ANOVA) and Bonferroni/Dunn post-hoc tests were
used to evaluate the main effects of lactate treatment on Annexin
V/7-AAD staining for the cell lines tested. Cell viability statistics
were analyzed with StatView software. All error bars on plots
express 6 SEM.
Supporting Information
Figure S1 24 h exposure to high lactate concentrations
do not decrease cell viability or increase cell death
responses when glucose is available in vitro. Cell viability
as measured by Annexin V 2/7-AAD – labeling (n = 3) in normal
human mammary epithelial cells (HMEC) (A), MCF7 (B) MDA-
MB-231 (C) and R3230Ac cells (D) show no significant changes 24
h after addition of exogenous sodium lactate (0240 mM) in the
context of available glucose. No significant changes in cell death
responses (Annexin V +/7-AAD –, Annexin V 2/7-AAD +, or
Annexin V+/7-AAD +) (n = 3) were observed in HMEC (E),
MCF7 (F) MDA-MB-231 (G) and R3230Ac cells (H) after
addition of exogenous sodium lactate (0-40 mM) in the context
of available glucose.
(TIF)
Figure S2 24 h exposure to high lactate concentrations
(-glucose) significantly decrease breast cancer cell
viability and increase cell death responses in human
breast cancer cells but not normal breast or R3230Ac
cells in vitro. Cell viability as measured by Annexin V 2/7-
AAD – labeling (n = 3) in normal human mammary epithelial cells
(HMEC) (A) and R3230Ac cells (D) show no significant change
after exposure to exogenous lactate for 24 h. MCF7 (B) and MDA-
MB-231 cells (C) show a significant decrease in unstained cells
after addition of 40 mM exogenous sodium lactate in the context
of available glucose (One-Way ANOVA, Bonferroni/Dunn post-
hoc test, # p#0.0006 compared to untreated control and all other
treatment groups). No significant changes in any cell death
response were seen in HMEC (E) or R3230Ac cells (H) after
lactate treatment in the context of glucose-deprivation. The
percentage of cells with Annexin V+/7-AAD + labeling was
significantly increased in MCF7 (F) and MDA-MB-231 (G) cells
after addition of 40 mM sodium lactate with glucose deprivation
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(n = 3, One-Way ANOVA, Bonferroni/Dunn post-hoc test, *p ,
0.0001 compared untreated control and to all other treated
groups).
(TIF)
Figure S3 MCT1 expression in breast cell lines. Total
protein expression of MCT1 in MCF7, MDA-MB-231 and
HMEC cells show MCT1 expression in MCF7 and HMEC but
not MDA-MB-231 cells (A). Total protein expression of MCT4 in
HMEC, MDA-MB-231, MCF7 and R3230Ac cells show
abundant MCT4 expression in MDA-MB-231 cells, low MCT4
expression in HMEC and no detectable MCT4 expression in
MCF7 or R3230Ac cells (B).
(TIF)
Figure S4 Compartmental model for 14C-labeled glu-
cose and lactate to analyze in vivo kinetic data. Cp =
glucose or lactate in the blood/plasma compartment, Ci =
glucose or lactate in the tumor compartment, Cs = glucose or
lactate in the SQ compartment. k0 = clearance by other tissues,
k1 = transfer rate into the tumor, k2 = transfer rate out of the
tumor, k3 = transfer rate into the subcutaneous tissue, k4 =
transfer rate out of the subcutaneous tissue.
(TIF)
Figure S5 MCF7 and MDA-MB-231 cell growth in
glucose-free, lactate-supplemented media vs. lactate-
free, high-glucose media. MCF7 and MDA-MB-231 cells
plated at equal densities and allowed to grow for 5 days in either
glucose-free, 20 mM lactate-supplemented media (n = 6) or high-
glucose media (n = 3). Five days after the media change, cells were
harvested and counted. MCF7 cell counts showed no difference
between media, but MDA-MB-231 cell counts were significantly
higher in the high-glucose (no lactate) media than in the glucose-
free, 20 mM lactate media (p = 0.005, Student’s T-test).
(TIF)
Figure S6 Normal human cells take up lactate and
export catabolites. HMQC plots of HMEC cell lysate (A) and
media (B) after 4.5 h incubation with 10 mM 13C-lactate, showing
evidence of labeled lactate (dark green ‘‘L’’) and glutamate (blue
‘‘G’’) peaks. 1H spectra of HUVEC cell lysate (bottom) and media
(top) after 24 h treatment with 5 mM 13C-lactate (C). The lysate
spectrum shows peaks corresponding to lactate, indicating uptake;
the media spectrum shows evidence of labeled lactate, alanine and
glutamate.
(TIF)
Figure S7 Control NMR spectra for R3230Ac cell media
alone or treated with no lactate + high or low CHC. 13C
spectrum of glucose-free, pyruvate-free, +glutamine (+10% FBS)
DMEM used for all in vitro NMR experiments show low
background levels of ubiquitous metabolites (A). 1H (B&C) or
13C (D&E) spectra of R3230Ac cell lysates (B&C) or media (D&E)
incubated for 4 h with no labeled lactate, no glucose + 0.1 mM
CHC (B&D) or 5 mM CHC (C&E), showing no labeled lactate.
(TIF)
Figure S8 1H NMR spectra of R3230Ac cell media
treated with 13C-lactate + CHC show evidence of
exportation of some endogenous lactate. 1H spectra of
R3230Ac cell media incubated with 20 mM 13C-lactate and
0.1 mM (A&C) or 5 mM (B&D) of CHC for 4 h (A&B) or 24 h
(C&D) show an abundance of 13C-lactate and incomplete
inhibition of endogenous lactate (green ‘‘Len’’) exportation.
(TIF)
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